circRNA & saRNA Synthesis Market - Global Forecast to 2036 | Market to Reach USD 4.82 Billion at 19.2% CAGR as RNA Therapeutics Pipelines and CDMO Demand Accelerate
Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "circRNA & SaRNA Synthesis Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.
The global circRNA & saRNA synthesis market was valued at USD 0.62 billion in 2025 and is projected to grow from an estimated USD 0.84 billion in 2026 to USD 4.82 billion by 2036. This represents a CAGR of 19.2% during the forecast period. Growth is being supported by expanding RNA therapeutic pipelines, biotechnology investment, next-generation vaccine development, clinical research, and demand for scalable RNA manufacturing technologies.
The report assesses market developments across RNA type, product and service, workflow stage, technology platform, application, end user, and geography. It also examines clinical programs, competitive strategies, manufacturing expansion, strategic collaborations, mergers and acquisitions, and emerging opportunities within the global RNA therapeutics ecosystem.
Market Growth Drivers
Increasing investment in RNA-based therapeutics is accelerating demand for circRNA and saRNA synthesis capabilities. The commercialization of mRNA vaccines validated RNA platforms and encouraged pharmaceutical and biotechnology companies to pursue technologies offering improved stability, sustained protein expression, dose efficiency, and manufacturing scalability.
Adoption is also expanding beyond infectious disease vaccines. CircRNA and saRNA platforms are being investigated for cancer immunotherapy, gene therapy, rare diseases, metabolic disorders, protein replacement therapies, and precision medicine. Their potential to support potent but temporary protein expression without permanent genomic modification is creating opportunities across a broad range of therapeutic programs.
Technological advances in in vitro transcription (IVT), enzymatic circularization, RNA purification, lipid nanoparticle (LNP) formulation, analytical characterization, artificial intelligence (AI)-enabled sequence optimization, and automated manufacturing are improving production efficiency and product quality. Companies are investing in GMP-grade facilities, specialized synthesis platforms, scalable workflows, and advanced quality control systems to support clinical and commercial development.
Contract development and manufacturing organizations (CDMOs) are becoming increasingly important as developers outsource process development, synthesis, purification, formulation, analytical testing, and GMP manufacturing. This trend is generating opportunities for specialized service providers with the infrastructure and technical expertise required for advanced RNA production.
Market expansion may be affected by complex manufacturing workflows, high production costs, limited process standardization, regulatory uncertainty, and purification and quality control challenges. Continued improvements in scalability, analytical validation, manufacturing consistency, and cost efficiency will be essential to broader commercialization.
Segment Analysis
By RNA type, the market includes circular RNA (circRNA) and self-amplifying RNA (saRNA). CircRNA is attracting investment across oncology, vaccines, regenerative medicine, and protein replacement therapy, supporting demand for improved circularization, purification, and manufacturing processes. SaRNA is expected to achieve strong growth as developers pursue dose-efficient vaccines, infectious disease prevention technologies, and immunotherapy applications.
Product and service categories include synthesis products, custom RNA synthesis services, process development services, analytical testing services, and manufacturing services. Custom synthesis holds a significant market position because pharmaceutical and biotechnology companies increasingly rely on external specialists for sequence design, synthesis optimization, purification, quality analysis, and GMP production. Manufacturing services are also expected to grow as more programs require clinical-grade and commercial-scale capacity.
Across workflow stages, clinical development is expanding as circRNA and saRNA candidates advance into trials for vaccines, oncology, and rare diseases. Commercial manufacturing is expected to gain momentum as candidate products progress toward regulatory review and market launch, increasing demand for reproducible and compliant production systems.
Key technology platforms include IVT, enzymatic circularization, RNA purification, and LNP formulation. IVT remains central to RNA synthesis, while advances in enzyme engineering and reaction optimization are improving yield and quality. LNP technologies are gaining importance as developers seek effective delivery systems for vaccines and therapeutics.
Vaccines represent a major application segment, supported by continued investment in next-generation RNA platforms. Cancer immunotherapy is expected to record significant growth through research into personalized cancer vaccines, immune modulation, and therapeutic protein expression. Gene therapy and protein replacement therapy applications are also expanding.
Pharmaceutical and biotechnology companies constitute the largest end-user segment because of their extensive RNA development pipelines and commercialization programs. CDMOs are expected to experience strong demand as emerging and established developers outsource specialized synthesis and manufacturing activities.
Regional Outlook
North America holds the largest market share, supported by advanced biotechnology infrastructure, substantial RNA therapeutics investment, strong venture capital activity, and the presence of leading pharmaceutical companies. Europe is benefiting from academic-industry collaboration, advanced therapeutics research, supportive regulatory frameworks, and investment in vaccine and gene therapy platforms.
Asia-Pacific is projected to register the fastest growth through 2036. Expanding pharmaceutical manufacturing, biotechnology investment, genomic medicine research, and clinical trial activity are strengthening RNA technology ecosystems in China, Japan, South Korea, India, and Singapore. Latin America and the Middle East & Africa offer emerging opportunities as healthcare investment, research collaboration, biotechnology infrastructure, and pharmaceutical manufacturing capabilities improve.
Competitive Landscape
Market participants are competing through proprietary RNA technologies, GMP manufacturing capacity, analytical testing capabilities, purification expertise, delivery platform integration, process automation, and computational sequence optimization. Strategic partnerships with pharmaceutical developers, biotechnology companies, academic institutions, research organizations, and CDMOs are helping providers expand technical capabilities and geographic reach.
Companies profiled in the report include TriLink BioTechnologies (Maravai LifeSciences), Aldevron (Danaher Corporation), Creative Biolabs, Thermo Fisher Scientific Inc., BioNTech SE, Moderna, Inc., Arcturus Therapeutics Holdings Inc., GenScript Biotech Corporation, eTheRNA Immunotherapies NV, and CureVac N.V.
Report Benefits
The report delivers actionable market intelligence for pharmaceutical companies, biotechnology firms, CDMOs, research organizations, investors, consultants, and technology providers seeking to evaluate opportunities across the global circRNA and saRNA synthesis ecosystem.
Key Topics Covered:
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Market Ecosystem
1.4 Currency and Limitations
1.4.1 Currency
1.4.2 Limitations
1.5 Key Stakeholders
2. Research Methodology
2.1 Research Approach
2.2 Data Collection & Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.3.3 Forecast Modeling
2.4 Data Triangulation
2.5 Assumptions
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Rapid Growth of RNA-based Therapeutics
4.2.1.2 Advantages of circRNA & saRNA
4.2.1.3 Expansion of mRNA Platform Ecosystem
4.2.1.4 Increasing Vaccine Development Activities
4.2.2 Restraints
4.2.2.1 Early-stage Market with Limited Commercialization
4.2.2.2 Manufacturing Complexity
4.2.2.3 Regulatory Uncertainty
4.2.3 Opportunities
4.2.3.1 Next-generation Vaccines (saRNA-based)
4.2.3.2 Gene Therapy Applications
4.2.3.3 AI-driven RNA Design Platforms
4.2.3.4 Expansion of CDMO Capabilities
4.2.4 Challenges
4.2.4.1 Scale-up and Purification Challenges
4.2.4.2 Delivery System Limitations
4.3 Technology & Synthesis Landscape
4.3.1 In Vitro Transcription (IVT)
4.3.2 Circularization Techniques (Enzymatic & Chemical)
4.3.3 Self-amplifying RNA Engineering
4.3.4 RNA Modification & Stabilization Techniques
4.3.5 Lipid Nanoparticle (LNP) Delivery Systems
4.3.6 Automation & Digital RNA Design
4.4 circRNA & saRNA Ecosystem
4.4.1 RNA Therapeutics Companies
4.4.2 CDMOs/CMOs
4.4.3 Reagent & Technology Providers
4.4.4 Academic & Research Institutes
4.4.5 Pharmaceutical Companies
4.5 Value Chain Analysis
4.5.1 Template Design (DNA Constructs)
4.5.2 RNA Synthesis (IVT)
4.5.3 Circularization / Amplification
4.5.4 Purification & Quality Control
4.5.5 Formulation & Delivery
4.6 Regulatory Landscape
4.6.1 Regulatory Framework for RNA Therapeutics
4.6.2 Clinical Trial Guidelines
4.6.3 GMP Requirements for RNA Manufacturing
4.7 Industry Trends
4.7.1 Rise of Self-amplifying RNA Vaccines
4.7.2 Increasing Investment in circRNA Platforms
4.7.3 Expansion of RNA CDMO Infrastructure
4.7.4 Integration of AI in RNA Design
4.8 Cost and Pricing Analysis
4.8.1 Cost by RNA Type (circRNA vs saRNA)
4.8.2 Manufacturing Cost Breakdown
4.8.3 CDMO Pricing Models
5. circRNA & saRNA Synthesis Market, by RNA Type
5.1 Introduction
5.2 Circular RNA (circRNA)
5.3 Self-amplifying RNA (saRNA)
6. circRNA & saRNA Synthesis Market, by Workflow Stage
6.1 Introduction
6.2 Template Design & DNA Synthesis
6.3 RNA Synthesis (IVT)
6.4 Circularization / Amplification
6.5 Purification & Quality Control
6.6 Formulation & Delivery
7. circRNA & saRNA Synthesis Market, by Product & Service
7.1 Introduction
7.2 Instruments & Equipment
7.2.1 IVT Systems
7.2.2 Purification Systems
7.2.3 Analytical Instruments
7.3 Consumables & Reagents
7.3.1 Enzymes & Kits
7.3.2 Nucleotides & Buffers
7.3.3 LNP Formulation Reagents
7.4 Services
7.4.1 Contract Manufacturing (CDMO/CMO)
7.4.2 Process Development Services
7.4.3 Analytical & QC Services
8. circRNA & saRNA Synthesis Market, by Technology Platform
8.1 IVT-based Synthesis Platforms
8.2 Enzymatic Circularization Technologies
8.3 Chemical Circularization Technologies
8.4 Self-amplifying RNA Engineering Platforms
8.5 LNP & Delivery Technologies
9. circRNA & saRNA Synthesis Market, by Application
9.1 Introduction
9.2 Vaccines
9.2.1 Infectious Disease Vaccines
9.2.2 Cancer Vaccines
9.3 Gene Therapy
9.4 Protein Replacement Therapy
9.5 Immunotherapy
9.6 Research Applications
10. circRNA & saRNA Synthesis Market, by End User
10.1 Biopharmaceutical Companies
10.2 Biotechnology Companies
10.3 CDMOs/CMOs
10.4 Academic & Research Institutes
11. circRNA & saRNA Synthesis Market, by Geography
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Netherlands
11.3.7 Sweden
11.3.8 Switzerland
11.3.9 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Australia
11.4.6 Singapore
11.4.7 Rest of Asia-Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America
11.6 Middle East & Africa
11.6.1 UAE
11.6.2 Saudi Arabia
11.6.3 South Africa
11.6.4 Rest of MEA
12. Competitive Landscape
12.1 Overview
12.2 Key Growth Strategies
12.3 Competitive Benchmarking
12.4 Competitive Dashboard
12.4.1 Industry Leaders
12.4.2 Technology Innovators
12.4.3 Emerging Players
12.5 Market Ranking/Positioning Analysis
13. Company Profiles
13.1 Moderna, Inc.
13.2 BioNTech SE
13.3 CureVac N.V.
13.4 Arcturus Therapeutics Holdings Inc.
13.5 Gritstone bio, Inc.
13.6 eTheRNA Immunotherapies NV
13.7 Ethris GmbH
13.8 Orbital Therapeutics
13.9 Laronde Inc.
13.10 TriLink BioTechnologies
13.11 Aldevron (Danaher)
13.12 AGC Biologics
13.13 WuXi AppTec
13.14 GenScript Biotech Corporation
13.15 Maravai LifeSciences
14. Appendix
14.1 Customization Options
14.2 Related Reports
For more information about this report visit https://www.researchandmarkets.com/r/dar6d1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.